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The current epidemic of infections caused by antibiotic-resistant
Gram-positive bacteria requires the discovery of new drug targets
and the development of new therapeutics. Lipoteichoic acid (LTA),
a cell wall polymer of Gram-positive bacteria, consists of 1,3-
polyglycerol-phosphate linked to glycolipid. LTA synthase (LtaS)
polymerizes polyglycerol-phosphate from phosphatidylglycerol, a
reaction that is essential for the growth of Gram-positive bacteria.
We screened small molecule libraries for compounds inhibiting
growth of Staphylococcus aureus but not of Gram-negative bacte-
ria. Compound 1771 [2-oxo-2-(5-phenyl-1,3,4-oxadiazol-2-ylamino)
ethyl 2-naphtho[2,1-b]furan-1-ylacetate] blocked phosphatidylgly-
cerol binding to LtaS and inhibited LTA synthesis in S. aureus and in
Escherichia coli expressing ltaS. Compound 1771 inhibited the
growth of antibiotic-resistant Gram-positive bacteria and prolon-
ged the survival of mice with lethal S. aureus challenge, validating
LtaS as a target for the development of antibiotics.
Methicillin-resistant Staphylococcus aureus (MRSA), glyco-peptide-resistant enterococci (GRE), and antibiotic-resistant
Clostridium difficile are examples for newly emerging or reemerging
drug-resistant Gram-positive pathogens with significant human
morbidity (1). As commensals of the human skin or intestine, these
microbes are continuously exposed to antibiotics and have evolved
resistance traits against commonly used therapeutics (2). To de-
velop novel antibiotics, a suitable molecular target must be iden-
tified (3). Ideal targets are found only in bacteria, not in humans,
and are positioned in the bacterial envelope, accessible for small
molecule inhibitors yet out of reach of multi–drug-resistance
transporters protecting cytoplasmic targets (3, 4). Such attributes
are found in penicillin-binding proteins and their inhibitors, β-lac-
tam or glycopeptide antibiotics; however, efforts to identify other
extracellular targets in Gram-positive bacteria have met with little
success (5).
Gram-positive bacteria incorporate lipoteichoic acids (LTAs)
into their envelope to scavenge magnesium ions, direct autolysins
to subcellular cell wall locations, and enable bacterial cell division
(6, 7). LTA from S. aureus and other bacteria is composed of 1,3-
polyglycerol-phosphate linked to glycolipid, which provides for
LTA anchoring in membranes (8). The glycolipid moiety is com-
posed of β-gentiobiosyldiacylglycerol [glucosyl-(1→6)-glucosyl-
(1→3)-diacylglycerol (Glc2-DAG)] (8, 9). PgcA (α-phosphoglu-
comutase), GtaB (UTP:α-glucose-1-phosphate uridyl transferase),
and YpfP (glycosyl-transferase) catalyze the three steps of glyco-
lipid synthesis (10–12), whereas LtaA transports Glc2-DAG across
the lipid bilayer (10). S. aureus ltaA, ypfP, pgcA, or gtaB mutants
cannot assemble Glc2-DAG but continue to synthesize poly-
glycerol-phosphate (10, 12). Glycolipid synthesis mutants are via-
ble; however, the variants display an increase in size and aberrant
cell shapes (10, 12).
LTA synthesis involves the polymerization of polyglycerol-
phosphate and its transfer to Glc2-DAG (13). This reaction is cat-
alyzed by LTA synthase (LtaS), a protein with five transmembrane
domains in its N-terminal domain and an extracellular sulfatase-like
domain (pfam00884) at the C-terminal end (14). Genetic depletion
or loss of the ltaS gene in S. aureus results in severe cell division
defects, a phenotype that is exacerbated when staphylococci are
grown at >30 °C (14, 15). Characterization of LtaS in Bacillus
anthracis, Bacillus subtilis, and Listeria monocytogenes confirmed
that membrane proteins with pfam00884 domains are indeed re-
sponsible for the synthesis of polyglycerol-phosphate LTA (7).
Where examined, ltaS mutants exhibited diminished viability, in-
creased cell size, and altered morphology (16–19). These results
suggested that LtaS of Gram-positive bacteria may represent an
extracellular target for the development of antibiotics against drug-
resistant Gram-positive bacteria. We here provide proof for this
hypothesis by isolating a small molecule inhibitor of LTA synthesis.
Results and Discussion
Compound 1771 Inhibits S. aureus Growth and LTA Synthesis. S. au-
reus variants that cannot express ltaS are unable to grow at 37 °C
(14). We took advantage of the temperature-sensitive phenotype
and screened compound libraries at the National Screening Lab-
oratory for the Regional Centers of Excellence in Biodefense and
Emerging Infectious Disease (NSRB) for candidate compounds
that inhibit growth of S. aureus at 42 °C. The primary screen
identified 73 compounds with greater than 90% growth inhibition
(Table S1). Thirty-one compounds were subjected to secondary
screening, which included dose–response analyses for growth in-
hibition of MRSA, as well as the Gram-negative microbe Escher-
ichia coli. Fifteen compounds specifically inhibited the growth of
MRSA but not of E. coli and displayed little or no cytotoxicity
when added to HL-60 cells, a human promyelocytic leukemia cell
(Table S1). One of these molecules, compound 1771 [2-oxo-2-(5-
phenyl-1,3,4-oxadiazol-2-ylamino)ethyl 2-naphtho[2,1-b]furan-
1-ylacetate], was identified as an inhibitor of LTA synthesis in
S. aureus as follows.
Overnight cultures of S. aureus were diluted and incubated with
increasing concentrations of compound 1771 (0, 2, or 5 μM),
resulting in increased reduction of growth (Fig. 1A). Extracts pre-
pared from staphylococcal cultures normalized to the same density
were analyzed by SDS/PAGE. Coomassie Blue staining of proteins
suggested that incubation of staphylococci with compound 1771 did
not alter the concentration of bacterial polypeptides (Fig. 1B).
However, immunoblotting with 1,3-polyglycerol phosphate-specific
monoclonal antibody (α-LTA) revealed that compound 1771 re-
duced the abundance of LTA (Fig. 1B). At a higher concentration
of 1771 (5 μM), LtaS-specific immunoreactive signals were reduced
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(Fig. 1C). As a control, the abundance of sortase A (SrtA), an
enzyme that links proteins to peptidoglycan, was not affected in
staphylococcal cultures treated with compound 1771 (Fig. 1C).
Expression of LtaS from S. aureus (ltaSSA) or B. anthracis
(ltaS2BA) in E. coli leads to the production of 1,3-polyglycerol
phosphate, as LTA synthase can use phosphatidylglycerol (PG)
substrate even from the membrane of Gram-negative bacteria
(Fig. 1, E and H). Unlike its antibiotic activity in S. aureus,
compound 1771 did not affect the growth of E. coli even at very
high concentrations (200 μM; Fig. 1 D and G). Strikingly, E. coli
synthesis of polyglycerol-phosphate via LtaSSA (Fig. 1E) or
LtaS2BA (Fig. 1H) was abrogated in the presence of compound
1771. Of note, E. coli expression of LtaS2BA, but not of LtaSSA,
was reduced in the presence of 1771 (Fig. 1 F and I).
Compound 1771 Inhibits the Growth of Gram-Positive Bacteria. To
examine the spectrum of antibiotic activity for compound 1771, we
analyzed Gram-positive bacteria harboring polyglycerol-phos-
phate LTA and LtaS homologs (Table S2). Compound 1771
inhibited the growth of antibiotic-resistant MRSA, e.g., the epi-
demic community-acquired isolate USA300 LAC, and VRE, i.e.,
vancomycin-resistant Enterococcus faeaclis and Enterococcus fae-
cium whose genomes harbor two ltaS homologs (Table S3). Gram-
positive bacteria with three (Clostridium perfringes) or four ltaS
homologs (B. cereus and B. anthracis) appeared to be more sus-
ceptible to compound 1771–mediated growth inhibition than
microbes with only one or two ltaS genes (Table S3).
Bacterial cultures incubated with or without sublethal concen-
trations of compound 1771 were examined by scanning electron
microscopy (SEM; Fig. 2). Treatment with compound 1771 dis-
persed cluster formation in S. aureus or chain formation in E.
faecalis and E. faecium (Fig. 2 A–C; Table S4). At higher magni-
fication of SEM images, compound 1771–treated staphylococci
and enterococci revealed an increase in cell size, as well as
deformations of their cell surface and shape (Fig. 2 A–C). In the
presence of compound 1771, B. anthracis formed longer chains of
vegetative cells and displayed undulating deformations of its cy-
lindrical cell shape (Fig. 2D; Fig. S1). Compound 1771–induced
morphological changes resemble those observed for S. aureus and
B. anthracis mutants with defects in LTA synthesis (14, 18). For
example, the chain length of the B. anthracis ltaS1/ltaS2 mutant is
increased compared with WT (Fig. S1A), and its ability to form
colonies is reduced by 1,000-fold (18).
Thin-section transmission electron microscopy (TEM) of S. au-
reus treatedwith compound1771 revealed thickeningand structural
disorganization of the cell wall envelope (Fig. 2E). The smooth
surface and structural organization of the envelope were perturbed
when staphylococciweregrown in thepresenceof40μMcompound
1771. Similar results were obtained with TEM images of thin-sec-
tioned enterococci and bacilli, which prompted measurements of
envelope thickness. The data revealed increases in envelope di-
ameter for S. aureus, E. faecalis, E. faecium, and B. anthracis grown
in the presence of compound 1771 (Fig. S1B; Table S5).
Mechanism of LTA Synthesis Inhibition for Compound 1771. The 3D
structure of the extracellular catalytic domain of LtaS has been
determined (17, 20). Overall, extracellular catalytic domain of
LtaS (eLtaS) assumes a sulfatase-like fold; however, its active site
is distinct from that of sulfatases (20). Threonine (T300) of LtaS
together with residues E255, D475, and H476 coordinate a man-
ganese ion and assemble to form a binding pocket for glycerol-
phosphate (20). As revealed from the cocrystal structure of eLtaS
with glycerol-phosphate, one oxygen atom of the phosphate group
is coordinated withMg2+, whereas the remainder of the phosphate
group is stabilized by hydrogen bonding with H416 and W354.
Hydroxyl side chains of glycerol-phosphate form hydrogen bonds
with H347, D349, and R356 (20). Catalysis has been proposed to
involve PG docking in the active site of eLtaS to enable nucleo-
philic attack from the deprotonated hydroxyl of T300, generating
a glycerol-phosphate-threonine intermediate and releasing diac-
ylglycerol. The glycerol-phosphate-threonine intermediate may
subsequently be resolved by the nucleophilic attack from the ter-
minal OH group of another PG, thereby extending the LTA chain
by one glycerol-phosphate moiety (20).
Incubation of purified eLtaS with compound 1771 followed
by MS analysis of the enzyme and inhibitor did not reveal the
formation of an eLtaS adduct or the cleavage of 1771. We used
size-exclusion HPLC with a BioBasic SEC300 column equili-
brated with 20 nmol nitro-benzoxadiazole glycerol-phosphate
Fig. 1. Compound 1771 inhibits LTA biosynthesis in S. aureus. (A) S. aureus
was grown in medium supplemented with either 1% DMSO (control) or two
subinhibitory concentrations of 1771 for 1 h, and the optical density at 600
nm (OD600 nm) was recorded. (B and C) Cultures shown in A were normal-
ized to the same density, and cells were lysed to prepare extracts for sepa-
ration on SDS/PAGE and Coomassie staining (B, Left) or immunoblot analyses
with antibodies specific for polyglycerol-phosphate (B, Right; α-LTA) or LtaS
(C, Upper; α-LtaS) and SrtA (C, Lower; α-SrtA). Native S. aureus LtaS is
detected as both full-length and processed proteins (70 and 49 kDa, re-
spectively). (D–I) Recombinant S. aureus LtaSSA (D–F) or B. anthracis LtaS2BA
(G–I) were expressed in E. coli, and synthesis of polyglycerol-phosphate was
detected by immunoblot. E. coli cultures induced (+) or noninduced (−) for
expression of LtaSSA (D) or LtaS2BA (G) were grown in medium supplemented
with either 1% DMSO (−) or 200 μM 1771 (+). Culture density measurements
were used to normalize cell lysates that were separated by SDS/PAGE and
analyzed by Coomassie staining (E and H, Left) or immunoblotting with
antibodies against LTA (E and H, Right) and LtaS (F and I). Recombinant
LtaSSA is detected as a double band like the native protein produced in
S. aureus, whereas only processed LtaS2BA is detected in E. coli extracts.
Molecular weight markers are indicated in kilodaltons.
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(NBD-GP) to measure binding of enzyme to substrate. Chro-
matography of 2 nmol eLtaS on the BioBasic SEC300 column
led to the elution of an enzyme·NBD-GP complex and absor-
bance at 460 nm (Fig. 3A). As a control, chromatography of 2
nmol sortase A, a transpeptidase that anchors surface proteins to
peptidoglycan and does not bind to glycerol-phosphate (21), did
not elute NBD-GP from a preequilibrated BioBasic SEC300
column (Fig. 3A). When the mobile HPLC phase was supple-
mented with 200 μM LTA synthesis inhibitor 1771, the ability of
eLtaS to elute NBD-GP complexes from the preequilibrated
column was abolished (Fig. 3A). eLtaS-mediated cleavage of
nitrobenzoxadiazole-PG (NBD-PGC6, with six carbon acyl chains)
was used to determine whether compound 1771 inhibits LTA
synthesis in vitro (22). In the presence of the enzyme (+eLtaS),
but not in its absence (−eLtaS), NBD-PGC6 (m/z 643.42) was
cleaved to generate NBD-DAGC6 (nitrobenzoxadiazole-diac-
ylglycerol, m/z 489.43), as revealed by HPLC and MS of chloro-
form-extracted samples, separating NBD-PGC6 substrate in the
aqueous phase (AP) from NBD-DAGC6 product in the organic
phase (OP; Fig. 3B). Addition of 100 μM compound 1771
inhibited eLtaS-mediated formation of NBD-DAGC6 product
from NBD-PGC6, indicating that the molecule inhibited LTA
synthesis in vitro (Fig. 3B).
The results in Fig. 3 suggest that compound 1771may bind to the
active site of eLtaS and prevent its association with PG. If so, the
distribution of hydrophobic and hydrophilic surface areas may be
similar for compound 1771 and PG. This prediction was examined
by generating 3D models with the Galaxy 3D Structure Generator
v2011.02 (www.molinspiration.com; Fig. 4A). The chemical desig-
nation of compound 1771 is 2-oxo-2-(5-phenyl-1,3,4-oxadiazol-2-
ylamino)ethyl 2-naphtho[2,1-b]furan-1-ylacetate, and its structural
formula can be arbitrarily divided into the R and naphthofuranyl
(NF) groups (Fig. 4B). The NF and R groups appear to mimic the
polar chains of PG (Fig. 4A). To analyze this possibility, we se-
lected three derivatives with an intact NF group and different R
groups for structure–activity relationships (Fig. 4C; 1771-1/-3).
Fig. 2. Structural changes of Gram-positive bacteria treated with com-
pound 1771. (A–D) Scanning electron micrographs of bacterial cultures
grown without or with compound 1771. Bacteria were cultured in BHI me-
dium supplemented with either 1% DMSO (− inhibitor) or subinhibitory
concentrations of 1771 (+ inhibitor): (A) S. aureus RN4220 ±30 μM 1771
scanned at 10,000× (Upper) and 80,000× (Lower) magnification; (B) E. fae-
calis V583 cells ±25 μM 1771 scanned at 10,000× (Upper) and 24,000×
(Lower); (C) E. faecium TX0016 cells ±20 μM 1771 scanned at 10,000× (Upper)
and 20,000× (Lower); (D) B. anthracis Sterne ±5 μM 1771 scanned at 5,000×
(Upper) or 10,000× (Lower). (E) Thin-section transmission electron micro-
graphs of S. aureus reveal a thickening of the envelope with visible defor-
mations in the presence of 30 or 40 μM compound 1771. (Upper) Electron
micrographs of staphylococci in the midst of cell division. Brackets in the
upper micrographs indicate the positions of enlarged image sections shown
below. M, plasma membrane; P, peptidoglycan layer containing teichoic
acids. Scale bars are indicated at the bottom left of each micrograph.
Fig. 3. Compound 1771 inhibits eLtaS binding to and cleavage of phos-
phatidylglycerol (PG) in vitro. (A) Size-exclusion HPLC of 2 nmol eLtaS or SrtA
on BioBasic SEC300 column preequilibrated with 20 nmol nitro-benzox-
adiazole PG containing chains of 16 carbon atoms (NBD-PGC16) reveals elution
of the NBD-PGC16·eLtaS complex with absorbance at 460 nm (blue trace), but
not formation of a NBD-PGC16·SrtA complex (green trace). Inclusion of 200 μM
compound 1771 in the mobile HPLC phase abolished the elution of NBD-
PGC16·eLtaS complex (red trace). (B) Using NBD-PGC6 with six carbon acyl
chains cleavage of 2 nmol substrate by 2 nmol eLtaS was detectable after 6-h
incubation at 37 °C. Chloroform extraction separated nonhydrolyzed NBD-
PGC6 [aqueous phase (AP)] from the hydrophobic reaction product nitro-
benzoxadiazole diacylglycerol (NBD-DAGC6), which segregated into the or-
ganic phase (OP). Both phases were analyzed by normal-phase HPLC on a diol
column (blue traces). Elution profiles were monitored by fluorescence (exci-
tation at 460 nm, emission at 534 nm). Identity of peak fractions was con-
firmed by mass spectrometry. Addition of 100 μM 1771 blocked NBD-DAGC6
production by eLtaS (red traces). A control reaction incubated for 6 h without
eLtaS did not contain detectable amounts of NBD-DAGC6 (green traces).
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Compared with compound 1771, none of these derivatives inhibi-
ted S. aureus growth (Fig. 4C; Table S6). Four compounds with
intact R group and different NF groups were also identified (Fig.
4D; 1771-4/-7). These derivatives yielded increasing inhibitory ac-
tivity on acquisition of either naphtho or furan rings (Fig. 4D; Table
S6). The relative loss of inhibitory activity by all seven structural
derivatives was similar for S. aureus and B. anthracis (Table S6).
Together, these findings indicate that compound 1771 is structur-
ally similar to PG and prevents the interaction between PG
and eLtaS.
Compound 1771 Prolongs the Survival of Mice with S. aureus Sepsis.
To examine the therapeutic value of compound 1771, we evaluated
its half-life in mice. Animals received a single i.p. injection of 32
mg/kg compound 1771. The blood of three animals was drawn 1, 6,
and 12 h following compound 1771 injection, and serum samples
were extracted with methanol and chloroform, separated by re-
versed-phase HPLC, and subjected to MS. This analysis revealed
two absorption peaks corresponding to cleavage fragments of
compound 1771, none of which retained inhibitory activity. Full
conversion of compound 1771 into its two cleavage fragments
occurred between 3 and 6 h following injection. The enzyme(s)
responsible for compound 1771 cleavage are not yet known, and it
is not yet clear whether compound 1771 can be modified to resist
cleavage while retaining its antibiotic activity.
To evaluate the therapeutic efficacy of compound 1771, we used
a mouse model of staphylococcal sepsis (23). Animals received i.p.
injections with 32 mg/kg of compound 1771 in 12-h intervals.
Treatment was initiated 24 h before challenge and terminated at
72 h after infection. Following challenge of mice via bloodstream
injection of 1 × 108 CFU S. aureusNewman, mock-treated animals
died of sepsis within 24 h (Fig. 5). In contrast, compound 1771–
treated animals survived up to 132 h, albeit all animals in this co-
hort eventually succumbed to the challenge (Fig. 5). Thus, al-
though compound 1771 is unstable in mice with rapid loss of
activity, its administration into animals delays time to death fol-
lowing a lethal challenge with S. aureus.
Selecting for S. aureus Variants with Increased Resistance to Compound
1771. The therapeutic value of many antibiotics is limited because
bacteria acquire resistance via spontaneous mutations that modify
the drug target (5). For example, streptomycin blocks ribosomal
protein synthesis (24, 25); however, mutations in rpsL, the struc-
tural gene for ribosomal protein S12, alter the polypeptide to
prevent antibiotic access to the ribosome (26). In contrast to
streptomycin-resistant mutants, which arise at frequencies <10−7
(Fig. S2A), S. aureusRN4220 formed rare small colonies only after
3–4 d of incubation on agar media with a 10–200 μM gradient of
compound 1771 (Fig. S2B). These observations suggest that re-
sistant colonies cannot be isolated from S. aureus at frequencies
≤2 × 10−9. When analyzed for their resistance phenotype, none of
Fig. 4. Structure-activity relationships of compound 1771. (A) 3D models showing the molecular hydrophobicity of PG (Left) and compound 1771 (Right).
Models were generated using Galaxy 3D Structure Generator v2011.02. Color coding for hydrophobic and hydrophilic areas are shown. (B) Structural formula
of 1771 with the chemical designation 2-oxo-2-(5-phenyl-1,3,4-oxadiazol-2-ylamino)ethyl 2-naphtho[2,1-b]furan-1-ylacetate. The naphthofuranyl group (NF)
is indicated with a gray line, and the remainder of the molecule is referred to as the R group. Growth inhibitory activity and structural formula of sub-
structures with intact naphthofuranyl group (C) or intact R region (D). Growth inhibitory activities were measured by adding compounds to cultures of S.
aureus RN4220 and displayed as mean with SDs of three independent experiments. Dose–response graphs were calculated by fitting data with variable slope
sigmoidal function using GraphPad Prism 5. Corresponding IC50 values are presented in Table S6.
Fig. 5. Compound 1771 increased the time to death in a mouse model of
S. aureus sepsis. Survival of cohorts of BALB/c mice (n = 15) challenged by
i.v. injection with 1 × 108 CFU S. aureus Newman. Animals were treated for
4 d starting 1 d before infection in 12-h intervals via i.p. injection with
either compound buffer (Mock) or 32 mg/kg weight of compound 1771.
Statistical significance was examined with the log-rank test: mock vs. 1771,
P < 0.0001. Data are representative of two independent experiments.
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the three independent colony isolates displayed significant changes
in either the minimal inhibitory concentration (MIC) or the IC50
values for compound 1771 (Table S7). Isolated strains produced
LtaS and LTA with similar abundance as their S. aureus parent and
did not harbor mutational alterations in the ltaS gene (Fig. S2C).
Thus, S. aureus selection on agar plates did not lead to variants with
a significant increase in resistance to compound 1771. This pheno-
type is similar to that reported for vancomycin (27), a cell wall active
antibiotic, which requires mutations in different genes for staphy-
lococci to acquire an intermediary resistance phenotype (28, 29).
LTA Synthesis Inhibitors as Infectious Disease Therapeutics.Owing to
the frequent use of antibiotics, members of the humanmicrobiome
continuously evolve drug resistance (30). For MRSA, drug re-
sistance is associated with therapeutic failure and increased mor-
tality of human infections (31, 32). Glycopeptide (vancomycin)
resistance has transferred from enterococci to MRSA (33); the
resulting VRSA strains are broadly antibiotic resistant and rep-
resent a global infectious threat (34, 35). Daptomycin and linezolid
have recently been licensed to address the threat of MRSA and
VRSA infections (36, 37). Nevertheless, staphylococci quickly
developed daptomycin and linezolid resistance, indicating that
additional antibotics are needed to combat S. aureus infections
(38). The crisis in antibiotic resistance applies also to other Gram-
positive pathogens, including C. difficile, E. faecium, E. faecalis,
Staphylococcus epidermidis, and Streptococcus pneumoniae (2, 39).
We explored LTA synthesis as a target for antibiotic therapy.
Growth of S. aureus, B. anthracis, L. monocytogenes, or B. subitilis
cannot occur without polyglycerol-phosphate LTA synthesis and
ltaS expression (14, 16, 17, 40). LtaS, the catalyst of LTA syn-
thesis, harbors five transmembrane domains and a C-terminal
catalytic domain that is found in bacteria but not in eukaryotes
(14). The unique presence of LTA and LtaS in the envelope of
bacterial species, the availability of the catalytic domain of LtaS
on the bacterial surface, and the requirement of LTA synthesis for
bacterial growth and cell division fulfill key target features for the
development of new antibiotics (41). Here we characterized
compound 1771 as an LTA synthesis inhibitor and demonstrated
its mechanism of action and ability to kill Gram-positive bacteria
with polyglycerol-phosphate LTA. We were unable to isolate
staphylococcal mutants with resistance against compound 1771,
suggesting that LTA synthesis may display target attributes similar
to peptidoglycan synthesis. Some Gram-positive bacteria, for ex-
ample,C. difficile and S. pneumoniae, synthesize LTAwith distinct
phosphate-polymer structures (42, 43); however, their mecha-
nisms of synthesis and possible inhibition by compound 1771 are
not yet known. Future work must develop compound 1771 further
to generate molecules that are stable in mammalian tissues and
display antibiotic activity against many different bacteria. Such
compounds may be useful therapeutics for human infectious
diseases caused by drug-resistant Gram-positive bacteria.
Experimental Procedures
High-Throughput Screen. The NSRB library of 167,405 compounds was
screened for molecules that inhibited the >90% growth of S. aureus RN4220
in Mueller-Hinton broth II supplemented with 0.005% Tween-80 in a 384-
well format by measuring the optical density at 600 nm (Z′ = 0.72–0.84).
A 98.9% (wt/wt) pure preparation of 2-oxo-2-(5-phenyl-1,3,4-oxadiazol-2-
ylamino)ethyl 2-naphtho[2,1-b]furan-1-ylacetate (compound 1771) was
obtained from Enamine (catalog no. T5526252).
Growth Inhibition. Cultures of E. coli, S. aureus, Clostridium perfringens, E.
faecalis, E. faecium, B. anthracis, and B. cereus were grown in the presence
or absence of inhibitor in 96-well microplates at 37 °C for 18–22 h and
monitored by measuring the optical density at 600 nm.
Inhibition of LTA Synthesis. Bacteria grown in the presence or absence of
compound 1771 were lysed in a bead beater, and cell extracts were subjected
to Coomassie-stained SDS/PAGE or immunoblotting using a monoclonal
antibody to detect LTA/polyglycerol-phosphate and polyclonal antibodies for
LtaS and SrtA.
eLtaS Inhibition. Size-exclusion HPLC was performed with a BioBasic
SEC300 column equilibrated in a 50 mM Hepes-KOH buffer, pH 7.5,
containing 10 μM MnCl2. The column was preequilibrated with 2 nmol
1-palmitoyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl}-
sn-glycero-3-[phospho-rac-(1-glycerol)] (Avanti Polar Lipids). Purified
eLtaS and SrtA (2 nmol) were injected, and chromatograms were recorded by
measuring absorbance at 460 nm.
Electron Microscopy. Samples were examined with a FEI Nova NanoSEM 200
scanning electron microscope operated with an acceleration voltage of 5 kV
at a distance of 5 mm. Thin-sectioned samples were viewed with a Tecnai F30
(Philips/FEI) transmission electron microscope (field emission gun operating
with a 300-kV accelerating voltage, using a magnification of 15,000–30,000×)
and a high performance CCD camera with 4 k × 4 k resolution.
Animal Experiments. Animal experiments were performed in accordance with
the institutional guidelines following experimental protocol review and
approval by the Institutional Biosafety Committee (IBC) and the Institutional
Animal Care and Use Committee (IACUC) at the University of Chicago. S.
aureus Newman (1 × 108 CFU suspended in 100 μL PBS) was injected into the
periorbital venous plexus of BALB/c mice (n = 15), and animals were moni-
tored for survival over 10 d. Animals received either two injections of in-
hibitor (32 mg/kg) or compound buffer (mock) separated by 12-h intervals
before infection and an additional six doses after infection.
Expanded text describing all experimental procedures is provided in SI
Experimental Procedures.
ACKNOWLEDGMENTS. We thank Sue Chiang, members of the National
Screening Laboratory for Regional Centers of Excellence in Biodefense and
Emerging Infectious Disease, and Hannah Maier for technical assistance, as
well as members of our laboratory for discussion. The authors acknowledge
membership within and support from the Region V Great Lakes Regional
Center of Excellence in Biodefense and Emerging Infectious Diseases
Consortium (National Institute of Allergy and Infectious Diseases Award 1-
U54-AI-057153).
1. Magiorakos AP, et al. (2012) Multidrug-resistant, extensively drug-resistant and
pandrug-resistant bacteria: An international expert proposal for interim standard
definitions for acquired resistance. Clin Microbiol Infect 18(3):268–281.
2. Neu HC (1992) The crisis in antibiotic resistance. Science 257(5073):1064–1073.
3. Payne DJ, Holmes DJ, Rosenberg M (2001) Delivering novel targets and antibiotics
from genomics. Curr Opin Investig Drugs 2(8):1028–1034.
4. Projan SJ (2003) Why is big Pharma getting out of antibacterial drug discovery? Curr
Opin Microbiol 6(5):427–430.
5. Walsh CT (2000) Molecular mechanisms that confer antibacterial drug resistance.
Nature 406(6797):775–781.
6. Neuhaus FC, Baddiley J (2003) A continuumof anionic charge: Structures and functions of
D-alanyl-teichoic acids in gram-positive bacteria.Microbiol Mol Biol Rev 67(4):686–723.
7. Reichmann NT, Gründling A (2011) Location, synthesis and function of glycolipids and
polyglycerolphosphate lipoteichoic acid in Gram-positive bacteria of the phylum Fir-
micutes. FEMS Microbiol Lett 319(2):97–105.
8. Fischer W (1990) Bacterial phosphoglycolipids and lipoteichoic acids. Handbook of
Lipid Research, ed Hanahan DJ (Plenum Press, New York), Vol 6, pp 123–234.
9. Duckworth M, Archibald AR, Baddiley J (1975) Lipoteichoic acid and lipoteichoic acid
carrier in Staphylococcus aureus H. FEBS Lett 53(2):176–179.
10. Gründling A, Schneewind O (2007) Genes required for glycolipid synthesis and lip-
oteichoic acid anchoring in Staphylococcus aureus. J Bacteriol 189(6):2521–2530.
11. Jorasch P, Warnecke DC, Lindner B, Zähringer U, Heinz E (2000) Novel processive and
nonprocessive glycosyltransferases from Staphylococcus aureus and Arabidopsis
thaliana synthesize glycoglycerolipids, glycophospholipids, glycosphingolipids and
glycosylsterols. Eur J Biochem 267(12):3770–3783.
12. Kiriukhin MY, Debabov DV, Shinabarger DL, Neuhaus FC (2001) Biosynthesis of the
glycolipid anchor in lipoteichoic acid of Staphylococcus aureus RN4220: Role of YpfP,
the diglucosyldiacylglycerol synthase. J Bacteriol 183(11):3506–3514.
13. Koch HU, Haas R, Fischer W (1984) The role of lipoteichoic acid biosynthesis in
membrane lipid metabolism of growing Staphylococcus aureus. Eur J Biochem 138(2):
357–363.
14. Gründling A, Schneewind O (2007) Synthesis of glycerol phosphate lipoteichoic acid in
Staphylococcus aureus. Proc Natl Acad Sci USA 104(20):8478–8483.
15. Oku Y, et al. (2009) Pleiotropic roles of polyglycerolphosphate synthase of lipoteichoic
acid in growth of Staphylococcus aureus cells. J Bacteriol 191(1):141–151.
16. Webb AJ, Karatsa-Dodgson M, Gründling A (2009) Two-enzyme systems for glycolipid
and polyglycerolphosphate lipoteichoic acid synthesis in Listeria monocytogenes.Mol
Microbiol 74(2):299–314.
Richter et al. PNAS | February 26, 2013 | vol. 110 | no. 9 | 3535
M
IC
RO
BI
O
LO
G
Y
17. Schirner K, Marles-Wright J, Lewis RJ, Errington J (2009) Distinct and essential mor-
phogenic functions for wall- and lipo-teichoic acids in Bacillus subtilis. EMBO J 28(7):
830–842.
18. Garufi G, et al. (2012) Synthesis of lipoteichoic acids in Bacillus anthracis. J Bacteriol
194(16):4312–4321.
19. Corrigan RM, Abbott JC, Burhenne H, Kaever V, Gründling A (2011) c-di-AMP is a new
second messenger in Staphylococcus aureus with a role in controlling cell size and
envelope stress. PLoS Pathog 7(9):e1002217.
20. Lu D, et al. (2009) Structure-based mechanism of lipoteichoic acid synthesis by
Staphylococcus aureus LtaS. Proc Natl Acad Sci USA 106(5):1584–1589.
21. Ton-That H, Liu G, Mazmanian SK, Faull KF, Schneewind O (1999) Purification and
characterization of sortase, the transpeptidase that cleaves surface proteins of
Staphylococcus aureus at the LPXTG motif. Proc Natl Acad Sci USA 96(22):
12424–12429.
22. Karatsa-Dodgson M, Wörmann ME, Gründling A (2010) In vitro analysis of the
Staphylococcus aureus lipoteichoic acid synthase enzyme using fluorescently labeled
lipids. J Bacteriol 192(20):5341–5349.
23. McAdow M, et al. (2011) Preventing Staphylococcus aureus sepsis through the in-
hibition of its agglutination in blood. PLoS Pathog 7(10):e1002307.
24. Anand N, Davis BD (1960) Damage by streptomycin to the cell membrane of Es-
cherichia coli. Nature 185:22–23.
25. Jones D, Metzger HJ, Schatz A, Waksman SA (1944) Control of Gram-negative bac-
teria in experimental animals by streptomycin. Science 100(2588):103–105.
26. Funatsu G, Wittmann HG (1972) Ribosomal proteins. 33. Location of amino-acid re-
placements in protein S12 isolated from Escherichia coli mutants resistant to strep-
tomycin. J Mol Biol 68(3):547–550.
27. McCormick MH, McGuire JM, Pittenger GE, Pittenger RC, Stark WM (1955-1956-1956)
Vancomycin, a new antibiotic. I. Chemical and biologic properties. Antibiot Annu 3:
606–611.
28. Walsh CT (1993) Vancomycin resistance: Decoding the molecular logic. Science 261
(5119):308–309.
29. Yamakawa J, et al. (2012) Heterogeneously vancomycin-intermediate Staphylococcus
aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: A
retrospective study. J Infect Chemother 18(3):406–409.
30. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF (2010) Community-associated metic-
illin-resistant Staphylococcus aureus. Lancet 375(9725):1557–1568.
31. Klevens RM, et al.; Active Bacterial Core surveillance (ABCs) MRSA Investigators (2007)
Invasive methicillin-resistant Staphylococcus aureus infections in the United States.
JAMA 298(15):1763–1771.
32. Klevens RM, Edwards JR, Gaynes RP, System NNIS; National Nosocomial Infections
Surveillance System (2008) The impact of antimicrobial-resistant, health care-associ-
ated infections on mortality in the United States. Clin Infect Dis 47(7):927–930.
33. Weigel LM, et al. (2003) Genetic analysis of a high-level vancomycin-resistant isolate
of Staphylococcus aureus. Science 302(5650):1569–1571.
34. Tenover FC, Biddle JW, Lancaster MV (2001) Increasing resistance to vancomycin and
other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 7(2):327–332.
35. Li M, et al. (2012) MRSA epidemic linked to a quickly spreading colonization and
virulence determinant. Nat Med 18(5):816–819.
36. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI; Daptomycin 98-01 and 99-01
Investigators (2004) The safety and efficacy of daptomycin for the treatment of
complicated skin and skin-structure infections. Clin Infect Dis 38(12):1673–1681.
37. Stevens DL, et al. (2002) Linezolid versus vancomycin for the treatment of methicillin-
resistant Staphylococcus aureus infections. Clin Infect Dis 34(11):1481–1490.
38. van Hal SJ, Paterson DL (2011) New Gram-positive antibiotics: Better than vancomy-
cin? Curr Opin Infect Dis 24(6):515–520.
39. Willems RJ, Hanage WP, Bessen DE, Feil EJ (2011) Population biology of Gram-positive
pathogens: high-risk clones for dissemination of antibiotic resistance. FEMS Microbiol
Rev 35(5):872–900.
40. Wörmann ME, Corrigan RM, Simpson PJ, Matthews SJ, Gründling A (2011) Enzymatic
activities and functional interdependencies of Bacillus subtilis lipoteichoic acid syn-
thesis enzymes. Mol Microbiol 79(3):566–583.
41. Projan SJ, Shlaes DM (2004) Antibacterial drug discovery: Is it all downhill from here?
Clin Microbiol Infect 10(Suppl 4):18–22.
42. Fischer W (1997) Pneumococcal lipoteichoic and teichoic acid.Microb Drug Resist 3(4):
309–325.
43. Reid CW, et al. (2012) Structural characterization of surface glycans from Clostridium
difficile. Carbohydr Res 354:65–73.
3536 | www.pnas.org/cgi/doi/10.1073/pnas.1217337110 Richter et al.
